The US Food and Drug Administration (FDA) has disbanded its Antiviral Drugs Advisory Committee, a committee charged with the review of products intended to treat HIV and AIDS, and transferred its authority to an existing advisory committee with a new name, the agency announced this week.
In a 19 March 2015 posting in the Federal Register, the government's daily record of agency actions, FDA said it was immediately disbanding the committee as it "is no longer needed."
The committee was "terminated" on 15 February 2015, FDA said.
The long-standing committee had been in existence since at least 1998, according to FDA records maintained on the agency's website. No specific reason was given for disbanding the committee, but it has not met since October 2013, and was convened only five times since January 2010.
The purpose of the committee was to evaluate "the safety and effectiveness of marketed and investigational human drug products for use in the treatment of acquired immune deficiency syndrome (AIDS), human immunodeficiency virus related illnesses, and other viral, fungal and mycobacterial infections."
The committee's reviews may be taken over by FDA's Anti-Infective Drugs Advisory Committee (AIDAC), which has a similar charge and meets more frequently. Advisory committees can also be reconvened if FDA determines there is a need for them at a later date.
Update: In a written response to Regulatory Focus, FDA spokeswoman Lyndsay Meyer confirmed FDA is transferring the Antiviral Drugs Advisory Committee's work to another committee, and re-naming another Advisory Committee.
The Anti-Infective Drugs Advisory Committee will now be known as the Antimicrobial Drugs Advisory Committee.
"All topics previously brought before the terminated Antiviral Drugs Advisory Committee will now be brought before the Antimicrobial Drugs Advisory Committee," Meyer explained.
Federal Register Announcement
Anti-Viral Drugs Advisory Committee Page